ClearPoint Neuro, Inc. (CLPT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$13.96-0.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CLPT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -16.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 24.6% |
Growth built into the price is above our model estimate.
The price assumes 40.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
CLPT — earnings miss
Dated 2026-08-03
of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: If revenue growth speeds up, it could signal a positive shift in the business. This would help clear doubts about its current loss-making status.
Supportive ifClearPoint reports revenue growth above 10% year over year in the next quarter.
Worry ifRevenue growth is still under 10% each year. This shows ongoing weakness.
Why it matters: ClearPoint's revenue guidance was adjusted down to $48M-$52M. Confirmation or further adjustment will signal the health of the business.
Worry ifQ3 revenue guidance remains within the $48M-$52M range without further downward adjustments.
Less concerning ifRevenue guidance is lowered again below $48M.
Why it matters: The revenue guidance of $48M-$52M shows management's confidence in growth. It shows the company can adapt its strategy.
Watch forManagement confirms revenue guidance remains within the $48M-$52M range during the next earnings call.
Also watch forManagement lowers revenue guidance again. This shows deeper problems in the growth strategy.
Why it matters: ClearPoint aims to expand clinical trials with biopharma partners. Progress here is crucial for future revenue growth.
Supportive ifAt least 10 clinical trials are enrolling patients. They are using ClearPoint technology.
Worry ifNo new trials announced or existing trials fail to enroll patients as expected.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$272 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $875 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,074 loss on $10,000 · 70.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better results show good cost control. This means operations are efficient.
Supportive ifOperating income improves from -$8.48M in Q1 to less negative in Q2.
Worry ifOperating income worsens or remains at -$8.48M or worse in Q2.
Why it matters: FDA approvals mean ClearPoint's partnerships are improving and revenue may grow.
Supportive ifAt least one biopharma partner receives FDA approval for a BLA submission.
Worry ifNo biopharma partners receive FDA approvals in the next six months.
Why it matters: Increased cash burn could signal deeper financial issues and affect future growth.
Worry ifCash burn increases beyond -$7.97M in Q2.
Less concerning ifCash burn decreases or stabilizes below -$7.97M in Q2.
Why it matters: Hitting this revenue target shows strong growth and progress toward yearly goals.
Supportive ifQ3 revenue reported at $12 million or more, showing continued growth.
Worry ifQ3 revenue under $10 million shows possible growth problems.
Why it matters: Another earnings miss would show ongoing problems. This could hurt investor trust.
Worry ifQ2 earnings were below what analysts expected.
Less concerning ifQ2 earnings meet or go above analyst expectations.
Why it matters: This will show if the strong growth trend can continue or if it is slowing.
Worry ifQ2 revenue growth was below 25% compared to last year.
Less concerning ifQ2 revenue growth reported at or above 25% year-over-year.
Why it matters: Good integration can lead to revenue and cost savings, improving financial health.
Supportive ifManagement says there are clear savings and revenue from the IRRAS deal.
Worry ifNo savings or delays in integration could mean problems.